The MarketReader Minute
đź’Š Biotech ETF Gains on Amgen Upgrade, Vertex Approval; MESO Soars on FDA Progress | Biotech Sector Insights
The iShares Biotechnology ETF advanced, led by Amgen’s upgrade to Overweight at Piper and Vertex’s EU approval for a cystic fibrosis therapy. MESO surged over 10% after aligning with the FDA on critical Revascor application components, drawing increased social media attention.